A very firm handshake: biotech's growing negotiating power

  title={A very firm handshake: biotech's growing negotiating power},
  author={Karl A Thiel},
  journal={Nature Biotechnology},
  • K. Thiel
  • Published 1 October 2005
  • Engineering
  • Nature Biotechnology
Even small biotech companies are taking more control of their product development as cash, competition, and other factors combine to bolster their negotiating power. 
Minimizing leakage of value from R&D alliances
Recent trends in alliance formation are summarized and approaches to minimize risk in alliances are discussed, which are growing in importance as alliance activity increases.
Shift toward early-stage deals favors biotechs
  • S. Lawrence
  • Biology, Engineering
    Nature Biotechnology
  • 2006
As biopharmaceutical companies move further into the pipeline in search of candidates, early stage deals are increasing in number and value.
Biotechnology financing, not acquisitions, for filling the pharma pipeline – a sustaining strategy
The pharma and biotechnology industry must re-examine this model and build an investment model that retains creativity and the entrepreneurial spirit that allows the time to yield multiple products.
Ensuring Quality Science From “R” to “D”: An Optimal Adoption Strategy for In-Licensing of Pharmaceutical Innovation
An optimal adoption strategy is proposed to evaluate the in-licensing opportunities for a pharmaceutical company as it finances several biotech partners who focus on the same therapeutic area and is modeled as a Poisson process during which small biotechs submit their outcomes to the pharmaceutical company.
Immunopharmacology: utilizing antibodies as ion channel modulators
This review discusses the use of ion channel antibodies and their associated small molecules as pharmacological tools, termed immunopharmacology, and some recent studies looking into clinical applications of immunophilearmacology and intrabodies.


Getting real about valuations in biotech
A lesser known valuation approach for biopharmaceutical products offers project managers and out-licensing biotech companies an edge in budget and license negotiations.
Goodbye Columbus! New NRDOs forego discovery
  • K. Thiel
  • Business
    Nature Biotechnology
  • 2004
Companies that eschew drug discovery in favor of in-licensing have captured a lot of attention and investment over the past few years. But are these young companies really chasing a sustainable
New estimates of drug development costs.
  • R. Frank
  • Biology
    Journal of health economics
  • 2003
Pfizer ’ s Funk
    Deal Statistics Quarterly,
    • In Vivo: The Business & Medicine Report,
    • 2005
    Crisis? What Crisis? A Fresh Diagnosis of Big Pharma’s R&D Productivity
    • Crunch (Marakon Associates,
    • 2004
    Critical Factors for Alliance Formation: Insights from the Deloitte Research Biotech Alliance Survey (Deloitte Research
    • 2005